» Articles » PMID: 22084509

Global Mesothelioma Deaths Reported to the World Health Organization Between 1994 and 2008

Overview
Specialty Public Health
Date 2011 Nov 16
PMID 22084509
Citations 170
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To carry out a descriptive analysis of mesothelioma deaths reported worldwide between 1994 and 2008.

Methods: We extracted data on mesothelioma deaths reported to the World Health Organization mortality database since 1994, when the disease was first recorded. We also sought information from other English-language sources. Crude and age-adjusted mortality rates were calculated and mortality trends were assessed from the annual percentage change in the age-adjusted mortality rate.

Findings: In total, 92,253 mesothelioma deaths were reported by 83 countries. Crude and age-adjusted mortality rates were 6.2 and 4.9 per million population, respectively. The age-adjusted mortality rate increased by 5.37% per year and consequently more than doubled during the study period. The mean age at death was 70 years and the male-to-female ratio was 3.6:1. The disease distribution by anatomical site was: pleura, 41.3%; peritoneum, 4.5%; pericardium, 0.3%; and unspecified sites, 43.1%. The geographical distribution of deaths was skewed towards high-income countries: the United States of America reported the highest number, while over 50% of all deaths occurred in Europe. In contrast, less than 12% occurred in middle- and low-income countries. The overall trend in the age-adjusted mortality rate was increasing in Europe and Japan but decreasing in the United States.

Conclusion: The number of mesothelioma deaths reported and the number of countries reporting deaths increased during the study period, probably due to better disease recognition and an increase in incidence. The different time trends observed between countries may be an early indication that the disease burden is slowly shifting towards those that have used asbestos more recently.

Citing Articles

Preclinical Efficacy and Proteomic Prediction of Molecular Targets for s-cal14.1b and s-cal14.2b Conotoxins with Antitumor Capacity in Xenografts of Malignant Pleural Mesothelioma.

Luna-Nophal A, Diaz-Castillo F, Izquierdo-Sanchez V, Velazquez-Fernandez J, Orozco-Morales M, Lara-Mejia L Mar Drugs. 2025; 23(1.

PMID: 39852534 PMC: 11767107. DOI: 10.3390/md23010032.


Clinical Perspectives and Novel Preclinical Models of Malignant Pleural Mesothelioma: A Critical Review.

Ebrahimi A, Ak G, Ozel C, Izgordu H, Ghorbanpoor H, Hassan S ACS Pharmacol Transl Sci. 2024; 7(11):3299-3333.

PMID: 39539262 PMC: 11555512. DOI: 10.1021/acsptsci.4c00324.


Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis.

Zafar A, Rashid A, Moeed A, Junaid Tahir M, Khan A, Shrateh O BMC Cancer. 2024; 24(1):1353.

PMID: 39501196 PMC: 11536716. DOI: 10.1186/s12885-024-13127-3.


Asbestos Exposure and Malignant Pleural Mesothelioma: A Systematic Review of Literature.

Santos C, Dos Anjos Dixe M, Sacadura-Leite E, Astoul P, Sousa-Uva A Port J Public Health. 2024; 40(3):188-202.

PMID: 39469260 PMC: 11320099. DOI: 10.1159/000527971.


The aftermath of asbestos prohibition in industry and its association with malignant mesothelioma in the south of Iran: An enduring predicament yet to be resolved.

Rezvani A, Shahriarirad R, Jahanshahi S, Fouladi D, Tavallali M, Ziaian B Health Sci Rep. 2024; 7(10):e70117.

PMID: 39377019 PMC: 11456676. DOI: 10.1002/hsr2.70117.


References
1.
. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997; 23(4):311-6. View

2.
Pukkala E, Martinsen J, Lynge E, Gunnarsdottir H, Sparen P, Tryggvadottir L . Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol. 2009; 48(5):646-790. DOI: 10.1080/02841860902913546. View

3.
Montanaro F, Bray F, Gennaro V, Merler E, Tyczynski J, Parkin D . Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control. 2003; 14(8):791-803. DOI: 10.1023/a:1026300619747. View

4.
Park E, Takahashi K, Hoshuyama T, Cheng T, Delgermaa V, Le G . Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011; 119(4):514-8. PMC: 3080934. DOI: 10.1289/ehp.1002845. View

5.
Tse L, Yu I, Goggins W, Clements M, Wang X, Au J . Are current or future mesothelioma epidemics in Hong Kong the tragic legacy of uncontrolled use of asbestos in the past?. Environ Health Perspect. 2010; 118(3):382-6. PMC: 2854767. DOI: 10.1289/ehp.0900868. View